A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2004
11/11/2004	US20040224347 Methods for identification, diagnosis, and treatment of breast cancer
11/11/2004	US20040224316 Using phosphodiesterase 4 inhibitor to treat cognitive training disorders; learning enhancement and enzyme inhibitors
11/11/2004	US20040224314 G-protein coupled receptors
11/11/2004	US20040224036 Dietary supplement and method for the treatment and prevention of digestive tract ulcers in equines and other animals
11/11/2004	US20040224033 Side effect-relieving agents and/or hypoglycemic effect enhancers for thiazolidine compounds
11/11/2004	US20040224031 synergistic insulin mimikers with lower toxicity since less vanadium compound needed; amine is semicarbazide-sensitive amine oxidase (SSAO) substrate; benzylamine and tyramine with sodium orthovanadate
11/11/2004	US20040224027 useful for tissue regeneration, particularly when used with orthopedic implants and drug delivery
11/11/2004	US20040224026 Collagen/polysaccharide bilayer matrix
11/11/2004	US20040224023 Compositions and methods for treating or preventing diseases of body passageways
11/11/2004	US20040224022 Collagen/polysaccharide bilayer matrix
11/11/2004	US20040224004 Methods and products for bad breath
11/11/2004	US20040224003 Drug formulations for coating medical devices
11/11/2004	US20040223975 Methods for treating cardiovascular diseases with botulinum toxin
11/11/2004	US20040223968 inhibiting a condition characterized by monocytic infiltrates such as atherosclerosis by administering an MCP-1 receptor antagonist that binds to an MCP-1 receptor polypeptide, especially a humanized or monoclonal antibody.
11/11/2004	US20040223962 administering a combination of a fibrinolytic agent and an antioxidant; particularly useful for treating individuals prior to or during long term flights or other situations involving extended immobility.
11/11/2004	US20040223958 Glutathione reductase for therapy and prophylaxis of AIDS
11/11/2004	US20040223956 Prebiotic and preservative uses of oil-emulsified probiotic encapsulations
11/11/2004	US20040223916 for a metered dose inhaler having part or all of its internal surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fluorocarbon polymers and having a wall with a thickness of 0.55 mm to 1.00 mm
11/11/2004	CA2562863A1 Blood sugar regulating agent comprising a natural dry product derived from soya bean seeds alone or in a mixture and preparation thereof
11/11/2004	CA2524175A1 Sugar intake-ability enhancer
11/11/2004	CA2524134A1 Adiponectin production enhancer
11/11/2004	CA2523868A1 Combinations comprising a protein tyrosine kinase receptor antagonist and a chemotherapeutic or naturally occurring, semi-synthetic of synthetic therapeutic agent for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
11/11/2004	CA2523339A1 Agent for preventing and healing constipation
11/11/2004	CA2523331A1 Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse
11/11/2004	CA2522971A1 Method of improved diuresis in individuals with impaired renal function
11/11/2004	CA2522431A1 Inhibitors of akt activity
11/11/2004	CA2522089A1 Prevention of hiv-1 infection by inhibition of rho-mediated reorganization and/or content alteration of cell membrane raft domains
11/11/2004	CA2521741A1 Pharmaceutical composition comprising a cathepsin s inhibitor and an opioid
11/11/2004	CA2521569A1 Combination of an aldosterone receptor antagonist and an anti-obesity agent
11/11/2004	CA2521152A1 Use of a topical medicament comprising riluzole
11/10/2004	EP1475639A2 Tumour-specific P450 protein
11/10/2004	EP1475099A1 Use of botulinum toxin to treat urinary incontinence
11/10/2004	EP1475096A1 Pharmaceutical composition for the treatment of herpes zoster
11/10/2004	EP1475086A2 Sibutramine metabolites
11/10/2004	EP1475085A1 Controlled-release formulations coated with aqueous dispersions of ethylcellulose
11/10/2004	EP1474687A2 Marks as modifiers of the p53 pathway and methods of use
11/10/2004	EP1474535A2 Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
11/10/2004	EP1474528A2 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
11/10/2004	EP1474448A1 Rrp sequences and knockout mice and uses thereof
11/10/2004	EP1474441A1 Tripeptides having a hydroxyproline ether of a substituted quinoline for the inhibition of ns3 (hepatitis c)
11/10/2004	EP1474438A2 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
11/10/2004	EP1474434A2 The eaat2 promoter and uses thereof
11/10/2004	EP1474421A1 Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity
11/10/2004	EP1474402A1 Salts of valsartan
11/10/2004	EP1474393A1 Aryl ureas as kinase inhibitors
11/10/2004	EP1474175A2 Agents that regulate apoptosis
11/10/2004	EP1474173A2 Composition and method for protecting labile active components
11/10/2004	EP1474171A1 Weight management system for obese animals
11/10/2004	EP1474163A2 Modification of feeding behavior
11/10/2004	EP1474162A1 Methods and compositions for the treatment of eye diseases
11/10/2004	EP1474158A2 Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
11/10/2004	EP1474153A2 Methods for particle-assisted polynucleotide immunization using a pulsed electric field
11/10/2004	EP1474148A1 Treatment of neuroblastoma
11/10/2004	EP1474147A1 Pyrimidine-based compounds useful as gsk-3 inhibitors
11/10/2004	EP1474145A1 Quinoline derivatives as npy antagonists
11/10/2004	EP1474139A2 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
11/10/2004	EP1474138A1 Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g)
11/10/2004	EP1474127A1 Biphenyl derivatives and their use as antiandrogenic agents
11/10/2004	EP1474121A2 Small molecule antagonists of bcl2 family proteins
11/10/2004	EP1474108A2 Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
11/10/2004	EP1474101A1 Anti-microbial composition comprising a metal ion chelating agent
11/10/2004	EP1474093A2 Granzyme b inhibitors
11/10/2004	EP1474069A1 Control of a biological function
11/10/2004	EP1473990A2 Cardiac-specific 11 beta hydroxysteroid dehydrogenase type 2 transgenic mice
11/10/2004	EP1267897B1 Treatment of congestive heart failure by pretreated autologous blood
11/10/2004	EP1140181B1 Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia
11/10/2004	EP1102567B1 Cardiac disease treatment device
11/10/2004	CN1545551A Human monoclonal antibody against hepatitis C virus E2 glycoprotein
11/10/2004	CN1545419A Antineoplastic combinations
11/10/2004	CN1545418A Method of increasing the presence of glutathione in cells
11/10/2004	CN1545415A Bone anabolic compounds and methods of use
11/10/2004	CN1544092A Ophthalmic compositions containing galactomannan polymers and borate
11/10/2004	CN1544091A Melanocyte suspension and its preparation for treating leukodermia
11/10/2004	CN1543932A Application of solid liposome nanoparticle for preparing pharmaceutical used for ion leading-in trandermal therapy
11/10/2004	CN1174956C Aminobenzophenones as inhibitors of IL-1 bata and TNF-alpha
11/10/2004	CN1174745C Use of coating as taste masking agent for oral preparation
11/10/2004	CN1174741C Surface modified particulate compositions of biologically active substances
11/09/2004	US6815555 Substituted phenol compounds useful for anesthesia and sedation
11/09/2004	US6815469 Injectable liquid oligomer-polymer composition consisting of at least one bioactive substance, at least one solid polymeric hydroxycarboxylic acid ester and at least one liquid oligomeric hydroxycarboxylic acid ester
11/09/2004	US6815451 1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists
11/09/2004	US6815442 Quinoxalinones for enhancing chemotherapy
11/09/2004	US6815441 Reaction products of taurultam and glucose
11/09/2004	US6815425 Administered with n-tert-butyl- alpha -(2-sulfophenyl)nitrone (spbn); neuroprotectants
11/09/2004	US6815416 Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor
11/09/2004	US6815415 Diagnosis and treatment of malignant neoplasms
11/09/2004	US6815414 Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders
11/09/2004	US6814983 Specific formulations of vitamins and minerals for supplementing those with high physiological stress levels such as during pregnancy and lactation
11/09/2004	US6814981 Ganglioside immunostimulating complexes and uses thereof
11/09/2004	US6814978 Process for preparing a soft tablet
11/09/2004	US6814976 Transdermal therapeutic system comprising a reservoir-type pressure-sensitive adhesive layer and a back layer with uni-directional resilience
11/09/2004	US6814972 Composition for prevention and/or treatment of vascular diseases, comprising propionyl L-carnitine and coenzyme Q10
11/09/2004	US6814964 Supramolecules containing binding and therapeutic molecules bound to hybridized nucleic acids
11/09/2004	US6814955 Aerosol comprises particles of chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine.
11/09/2004	US6814954 Delivery of compounds for the treatment of Parkinsons through an inhalation route
11/09/2004	US6814953 Bronchodilating compositions and methods
11/09/2004	CA2280718C Administration of an injectable antibiotic in the ear of an animal
11/09/2004	CA2273080C Mutants of the lag-3 proteins, products for the expression of these mutants and use
11/09/2004	CA2265824C Antifungal combination therapy
11/09/2004	CA2260750C Methods for providing safe local anesthesia
11/09/2004	CA2109572C Method for reducing side-effects of a drug

1 ... 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 ... 1151